9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for hepatocellular carcinoma (HCC). Its application has changed the status of sorafenib as the only first-line TKI treatment for HCC for more than a decade. Evidence has shown that lenvatinib possesses antitumor proliferation and immunomodulatory activity in preclinical studies. In comparison, lenvatinib was non-inferior to sorafenib in overall survival (OS), and even shows superiority with regard to all the secondary efficacy endpoints. Immune-checkpoint inhibitors(ICIs)are now being incorporated into HCC treatment. Positive outcomes have been achieved in the combination of lenvatinib plus ICIs, bringing broader prospects for HCC. This review presents an overview on the therapeutic mechanisms and clinical efficacy of lenvatinib in HCC, and we discuss the future perspectives of lenvatinib in HCC management with focus on biomarker-guided precision medicine.

          Related collections

          Author and article information

          Journal
          Biochim Biophys Acta Rev Cancer
          Biochimica et biophysica acta. Reviews on cancer
          Elsevier BV
          1879-2561
          0304-419X
          August 2020
          : 1874
          : 1
          Affiliations
          [1 ] School of Life Sciences, Fudan University, Shanghai 200438, China. Electronic address: 18321796036@163.com.
          [2 ] School of Life Sciences, Fudan University, Shanghai 200438, China. Electronic address: 1759312471@qq.com.
          [3 ] School of Life Sciences, Fudan University, Shanghai 200438, China. Electronic address: 19110700092@fudan.edu.cn.
          [4 ] International Cooperation Laboratory of Signal Transduction, Eastern Hepatobiliary Surgery Institute, China. Electronic address: Chenlei@smmu.edu.cn.
          Article
          S0304-419X(20)30110-4
          10.1016/j.bbcan.2020.188391
          32659252
          052b77e3-6ed5-428a-be61-9232bd96c675
          History

          HCC,Lenvatinib,Precision medicine,Molecular mechanisms,Clinical efficacy

          Comments

          Comment on this article